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Background: It has been shown that proteasome inhibition leads to growth arrest in the G1 phase of the cell
cycle and/or induction of apoptosis. However, it was found that some of these inhibitors do not induce
apoptosis in several human normal cell lines. This selective activity makes proteasome inhibition a promising
target for new generation of anticancer drugs. Clinical validation of the proteasome, as a therapeutic target in
oncology, has been provided by the dipeptide boronic acid derivative; bortezomib. Bortezomib has proven to
be effective as a single agent in multiple myeloma and some forms of non-Hodgkin’s lymphoma. Syringic acid
(4-hydroxy-3,5-dimethoxybenzoic acid, 1), a known phenolic acid, was isolated from the methanol extract of
Tamarix aucheriana and was shown to possess proteasome inhibitory activity.
Methods: Using Surflex-Dock program interfaced with SYBYL, the docking affinities of syringic acid and its proposed
derivatives to 20S proteasome were studied. Several derivatives were virtually proposed, however, five derivatives:
benzyl 4-hydroxy-3,5-dimethoxybenzoate (2), benzyl 4-(benzyloxy)-3,5-dimethoxybenzoate (3), 3'-methoxybenzyl
3,5-dimethoxy-4-(3'-methoxybenzyloxy)benzoate (4), 3'-methoxybenzyl 4-hydroxy-3,5-dimethoxybenzoate (5) and
3',5'-dimethoxybenzyl 4-hydroxy-3,5-dimethoxybenzoate (6), were selected based on high docking scores,
synthesized, and tested for their anti-mitogenic activity against human colorectal, breast and malignant
melanoma cells as well as normal human fibroblast cells.
Results: Derivatives 2, 5, and 6 showed selective dose-dependent anti-mitogenic effect against human malignant
melanoma cell lines HTB66 and HTB68 with minimal cytotoxicity on colorectal and breast cancer cells as well as
normal human fibroblast cells. Derivatives 2, 5 and 6 significantly (p ≤ 0.0001) inhibited the various proteasomal
chymotrypsin, PGPH, and trypsin like activities. They growth arrested the growth of HTB66 cells at G1 and G2-phases.
They also arrested the growth of HTB68 cells at S- and G2-phase, respectively. Moreover, derivatives 2, 5, and 6
markedly induced apoptosis (≥ 90%) in both HTB66 and HTB68.
Conclusions: Computer-derived syringic acid derivatives possess selective anti-mitogenic activity on human malignant
melanoma cells that may be attributed to perturbation of cell cycle, induction of apoptosis and inhibition of various
26S proteasomal activities.
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It is estimated that 10 million people worldwide are
diagnosed with cancer and about 6.2 million die from
the disease every year [1,2]. Tumour cells often have
multiple alterations in their apoptotic mechanisms and/
or signalling pathways that lead to increased levels of
growth and proliferation [3,4]. Overriding these mutations
stimulates the apoptotic signalling pathway, leading to
tumour cell death, which is a significant area of focus
in anticancer drug research.
Proteasomes are gaining escalating interest since they
play a key role in cancer cell proliferation, inhibition of
chemotherapy-induced apoptosis and drug resistant
development. Proteasome is a multicatalytic protease
complex that degrades most endogenous proteins,
including misfolded or damaged proteins, to ensure
normal cellular function. Proteasome degrades the
majority of intracellular proteins, including p27kip1, p21,
IkB-α, Bax, cyclins, metabolic enzymes, transcription
factors and the tumour suppressor protein p53. In
addition, several of its enzymatic activities (proteolytic,
ATPase, de-ubiquitinating) demonstrate key roles in
protein quality control, antigen processing, signal trans-
duction, cell-cycle control, cell differentiation and apop-
tosis [5-7]. Therefore, proteasome is an attractive target
for a combined chemoprevention/chemotherapeutic ap-
proaches and thus ideal for cancer therapy.
Recently, it has been shown that proteasome inhibition
leads to growth arrest in the G1 phase of the cell cycle
and/or induction of apoptosis [8,9]. However, it was
found that some of these inhibitors do not induce apop-
tosis in several human normal cell lines [9-11]. This se-
lective activity makes proteasome inhibition a promising
target for new generation of anticancer drugs.
Clinical validation of the proteasome, as a therapeutic
target in oncology, has been provided by the dipeptide
boronic acid derivative; bortezomib [12]. Bortezomib has
proven to be effective as a single agent in multiple myeloma
[13] and some forms of non-Hodgkin’s lymphoma [14].
Despite the acceptable therapeutic index, patients
treated with this drug in phases I and II clinical trials
manifest several toxic side effects, including diarrhoea,
fatigue, fluid retention, hypokalaemia, hyponatremia,
thrombocytopenia, anaemia, anorexia, neutropenia and
pyrexia [15,16]. These side effects justify the need to
discover other safer proteasome inhibitors that are
more readily available than synthetic drugs, e.g., natural
products or nutritional compounds with pharmacophores
similar to those of authentic proteasome inhibitors.
The pursuit for nontoxic natural proteasome inhibitors
has been stimulated by the fact that several natural
products, such as green tea polyphenols and the anti-
biotic lactacystin, have been shown to potently inhibit
proteasome. One of the most promising drug candidatesof this type is salinosporamide A, from the bacterium
Salinispora tropica [17,18]. The introduction of salinos-
poramide into phase I clinical trials inspired the search
for additional natural proteasome inhibitory scaffolds.
Over the past two decades, only one FDA-approved drug
(sunitinib for renal carcinoma in 2005) was discovered
based on high-throughput screening of combinatorial
chemistry libraries [19,20]. Natural product-based drugs
(parent compounds, analogues, and mimics) are still
the major new entities source among the FDA-approved
drugs (57.7% of all drugs) [21,22].
TMC-95A, B, C and D, cyclic polypeptides isolated
from Apiospora montagnei, were shown to reduce tryp-
sin-like and peptidylglutamyl-peptide hydrolysing activ-
ity of the proteasomal 20S core particle at a nonmolar
range. This activity data is indicative of a highly selective
inhibitor for the 20S proteasome [21,22].
Since these cyclic polypeptides are not related to any pre-
viously reported proteasome inhibitor, their proteasome
binding mode was determined through crystallographic
analysis. Crystal structure of TMC-95A-proteasome com-
plex indicates a non-covalent linkage to the active β-
subunits, Figure 1. This binding mode does not modify
these β-subunits’ N-terminal threonine residue, in contrast
to all previous structurally analysed proteasome-inhibitor
complexes.
The natural product syringic acid, known chemically as
4-hydroxy-3,5-dimethoxybenzoic acid, was recently iso-
lated from the methanol extract of Tamarix aucheriana.
Additionally, the preliminary results showed that this
phenolic acid possesses potent anti-proliferative activity
against human colorectal and breast cancer cells.
Computer-assisted drug design technique plays an
important role in drug design and discovery, as well as
in preliminary prediction of mechanisms via in silico
exploration of possible binding sites of the target
macromolecule in a non-covalent fashion [23,24].
This report accounts on attempts made to optimize
syringic acid proteasome inhibitory activity via rational
design of some active semisynthetic derivatives. Several
virtual semisynthetic syringic acid derivatives were designed
and docked at the active site of 20S proteasome core
particle. Syringic acid derivatives with high docking
scores were selected, synthesized and their proteasome
inhibitory activities were studied in vitro.
Results and discussion
Chemistry
Eighteen virtual aromatic, heteroaromatic, aliphatic, and
olefinic esters, thioesters, carbamates, and ethers of syringic
acid were proposed to explore the electronic space around
the carboxy and free phenol groups. These structures
were docked at the active site of available crystal struc-
tures of 20S proteasome (PDB 1R0P and 1JD2). Of these
Figure 1 Overlay docking alignment of TMC-95A. Compound TMC-95A docked into in the active site of 20S yeast proteasome (PDB code:
1JD2). Selected structure is of 3D resolution 3.0 Å.
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assessed in this study, were selected for chemical synthe-
sis. This selection was based upon two criteria; the high
docking score and the feasibility of chemical synthesis.
The route used for the semisynthesis of these derivatives
is shown in Scheme 1. These derivatives were synthesized
directly, in good yields, by refluxing equimolar quantities
of syringic acid with benzyl halides in N,N-dimethyl
formamide, followed by reaction work up, extraction
and chromatographic purification. The identity of the
pure derivatives was confirmed based on their spectral
data.
Biological activity
Dose-dependent anti-mitogenic effect of syringic acid
derivatives on human cancer cells and normal human
fibroblast
Derivative 2 The dose-dependent antimitogenic activity
of 2 (0.1 – 2 mg /mL) towards a panel of human breast
(HTB26, HTB132), malignant melanoma (HTB66) and
colorectal (CCL233, CCL235) cancer cell lines as well as
normal human fibroblast (CRL1554) were tested after
144 h of treatment.
All tested cancer cell lines, except melanoma, showed
a maximum growth inhibition of about 20% (Figure 2).
Melanoma cells exhibited a dose-dependent growth
inhibition. However, normal human fibroblast showed a
marked growth inhibition at a concentration higher
than 1.0 mg/mL (Figure 2). The anti-mitogenic activity
of 2 towards malignant melanoma was retested using
lower concentrations of (50, 150, 259, 350 and 400 μg/mL) and less exposure time, 24 h. Under these condi-
tions, 2, at 50–400 μg/mL, exerted a marked significant
growth inhibition on human malignant melanoma cells
HTB66 (% mean of cytotoxicity = 52.2 ± 8, IC50 = 266.7 μg/
mL, p ≤ 0.0001) and HTB68 (% mean of cytotoxicity =
47.2 ± 9, IC50 = 280 μg/mL, p ≤ 0.002) compared to the
effect of 2 on normal human fibroblast CRL1554 (% mean
of cytotoxicity = 12.7 ± 2.9, Figure 3).
These results are consistent with previous studies on
the growth inhibitory effect of other plant phenolic acids
against different types of cancer cells [25,26].
Derivatives 3 and 4 These derivatives were tested for
their anti-mitogenic activities, at different concentrations
and 144 h exposure time towards human colorectal,
breast, malignant melanoma cancer cell lines and normal
human fibroblast. Derivatives 3 and 4 showed a maximum
growth inhibition, between 25-40%, on human melanoma
(HTB66, 40%), colorectal (CCL235, 30%) and breast
(HTB132, 25%) cancer cell lines. Meanwhile, colorectal
(CCL233) and breast (HTB26) cancer cell lines as well as
normal human fibroblast CRL1554 showed a maximum
growth inhibition of 10%. These results showed that
derivatives 3 and 4 possess low anti-mitogenic activities
(Figure 2). Derivatives 3 and 4 were not further investi-
gated due to their low antimitogenic activities and low
synthetic yield.
Derivatives 5 and 6 Dose-dependent anti-proliferative
effects of derivatives 5 and 6 towards human colorectal,































































Scheme 1 Semisynthetic routes for syringic acid derivatives 2–6.
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The inhibition study indicated that derivative 5 exerted a
higher growth inhibition of malignant melanoma (> 60%)
compared to other cancer cell lines (≤ 30%) and normal
fibroblast (20%) that were slightly affected (Figure 3).
Lower concentrations of derivative 5 (100–800 μg/mL)
were retested against human malignant melanoma and
normal fibroblast. It showed a higher growth inhibitory
effect on malignant melanoma HTB66 (% mean of cyto-
toxicity = 21 ± 4, IC40 = 600 μg/mL, p ≤ 0.115) and HTB68
(% mean of cytotoxicity = 49 ± 9, IC40 = 440 μg/mL, p ≤
0.001) compared to the normal fibroblast (% mean of
cytotoxicity = 7.8 ± 2) (Figure 3). On the other hand, 6
had a maximum growth inhibitory effect of 20% on the
tested cancer cell lines except for human malignant
melanoma (HTB66) cells that were markedly inhibited
in a dose-dependent manner. However, normal fibroblast
cells were also greatly affected. So, lower concentrations of
derivative 6 (260, 280, 320, 380 and 400 μg/mL) were
retested after 24 h of treatment. Derivative 6 (260–400 μg/mL) produced a greater growth inhibition of HTB66 (%
mean of cytotoxicity = 33.2 ± 1, IC40 = 398.7 μg/mL, p ≤
0.0001) and HTB68 (% mean of cytotoxicity = 31.5 ± 2.7,
IC40 = 380.6 μg/mL, p ≤ 0.0001) compared to the normal
human fibroblast CRL1554 (% mean of cytotoxicity =
3.5 ± 0.9, Figure 3).
These results are in agreement with those reported
for other phenolic acids in different types of cancers
[27-30].Inhibition of proteasomal activities in human malignant
melanoma cell extracts by derivatives 2, 5 and 6
The potential of derivatives 2, 5 and 6 to inhibit the
proteasomal activities in human malignant melanoma
cell extracts were evaluated by measuring the various
proteasomal proteolytic activities, chymotrypsin-like, tryp-
sin-like and PGPH, after treatment with derivative 2 (2
mg/mL), derivative 5 (1.3 mg/mL) or derivative 6 (1.75
mg/mL).
Figure 2 Dose-dependent anti-mitogenic effect of derivatives 2–6 on different human cancer cell lines. Human cancer cell lines (CCL233,
CCL235, HTB26, HTB132, HTB 66, HTB 68) and normal fibroblast (CRL1554) were plated (27x103 cells/well) into 96 well plates and incubated at
37°C in a CO2 and non-CO2 incubators. Cells were treated with different concentrations of derivatives (0.1-2 mg/mL) for 144 h. The cell growth
was measured by MTT assay.
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0.0001) inhibition of proteasomal chymotrypsin-like activ-
ity. Moreover, derivatives 2, 5 and 6 exhibited a significant
(p ≤ 0.0001) inhibition of proteasomal PGPH-like activity.
Furthermore, derivatives 2, 5 and 6 exerted a significant
reduction (p ≤ 0.0001) of proteasomal trypsin-like activity
(Figure 4) compared to untreated malignant melanoma.
Derivatives 3 and 4 were not tested because of their low
anti-mitogenic activities and low synthetic yields, as well.
These results are consistent with those reported for
other natural products, that exhibited anti-proteasomal
activity in various human cancers, such as epigallocatechin
gallate (EGCG) [31-33], gallic acid [25], quercetin
[26], apigenin, a mixture of quercetin and myricetin
[34], curcumin [35-37], genistein [38] and EGCG ana-
logues [39,40].
How derivatives 2, 5 and 6 disturb the cellular prote-
asome function yet to be discovered. They could inhibit
the proteasome function directly by blocking the 20S
proteasome core cavity, or indirectly either by inhibiting
the ubiquitin isopeptidase activity, or through the gener-
ation of oxidative stress. Inhibition of isopeptidase activity
probably leads to the accumulation of ubiquitin-protein
conjugate and polyubiquitin because of the lack of ubiqui-tin recycling process. Excessive accumulation of ubiquitin-
protein conjugates could conceivably create proteasomal
dysfunction. Derivatives 2, 5 and 6 may also induce pro-
teasomal malfunction through the generation of oxidative
stress. Oxidative stress is known to inhibit the proteasome
function [41,42]. Impairment of proteasome function by
derivatives 2, 5 and 6 warrants further investigation.
Effect of syringic acid derivatives on human malignant
melanoma cell cycle
Treatment of human malignant melanoma cell line HTB66
with 1.3 mg/mL of 2 for 24 h arrested the growth of
HTB66 cells at G1-phase (33.5% vs. 30.9% for UT) and
G2-phase (52.7% vs. 50.9%; untreated, UT) with corre-
sponding decrease in HTB66 cells in S-phase (13.7% vs.
18% for UT) (Figure 5a). On the other hand, derivative
2 arrested the growth of human malignant melanoma
HTB-68 at S-phase (33.4% vs. 28.1% for UT) with cor-
responding decrease in HTB-68 cells in G1-phase
(43.4% vs. 47.8% for UT) and G2-phase (23.1% vs. 23.9
for UT) (Figure 5b). Moreover, treatment of malignant
melanoma cell line HTB66 with 5 (1.9 mg/mL) for 24 h
arrested HTB66 growth at S-phase (23% vs. 17.5 for
UT) and G1-phase (33.6% vs. 32.2 for UT) with
Figure 4 Inhibition of 26S proteasomal activities of human
malignant melanoma cells treated with derivatives 2, 5 and 6.
Human melanoma cells HTB68 were plated (1 × 106 cells/well) in 12
well plates and incubated 24 h at 37°C in CO2 incubator. Cells were
then treated with 2 (1.5 mg/mL), 5 (2.6 mg/mL) and 6 (1.75 mg/mL) or
epoxomicin (50 ng/mL) as a positive control for 24 h. Cells were
harvested and cytosolic fractions were prepared using nuclear/cytosol
fractionation assay kit (Bio-Vision incorporated). The chymotrypsin-like
activity, PGPH activity and trypsin-like activity of 26S proteasome was
monitored using fluorogenic substrates in fluorometer with an
excitation filter of 360 nm and emission filter of 460 nm.
Figure 3 Dose-dependent anti-mitogenic effect of derivatives 2,
5 and 6 on human melanoma cancer cell lines. Human
melanoma cell lines (HTB66 and HTB68) and normal fibroblast
(CRL1554) were plated (27x103 cells/well) into 96 well plates and
incubated at 37°C in a CO2 incubator. Cells were treated with 2
(50–400 μg/mL), 5 (100–800 μg/mL), and 6 (260–400 μg/mL) for 24 h.
The cell growth was measured by MTT assay.
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(43.3% vs. 50.2% for UT) (Figure 6a). On the other
hand, 5 arrested HTB68 growth at G2-phase (28.1% vs.
24.9% for UT) with corresponding decrease in HTB68
cells at G1-phase (47.9% vs. 49% for UT) and S-phase
(23.8% vs. 26% for UT, Figure 6b).
Induction of apoptosis in human malignant melanoma
treated with derivatives 2 and 5
The induction of apoptosis has been recognized as an
effective tool in the therapeutic treatment of many tu-
mours. In the present study, treatment of human ma-
lignant melanoma cell lines HTB66 and HTB68 with
1.3 mg/mL of 2 for 24 h, markedly induced apoptosis
in HTB66 (% early apoptosis = 90.8% and % late apop-
tosis = 7.6% vs. 12.5% and 2.7% for early and late apop-
tosis, respectively, in UT) (Figure 7a) and HTB68 (%
early apoptosis = 90.8% and % late apoptosis = 7.6% vs.8.6% and 1.4% for early and late apoptosis, respectively,
in UT, Figure 7b). Similar marked induction of apop-
tosis was noticed when malignant melanoma cell lines
Figure 6 Flow cytometric analysis of cell cycle distribution of
human melanoma cancer cells treated with 5. The human
melanoma cancer cell lines HTB66 (a) and 68 (b) were treated with
5 (1.9 mg/mL), for 24 h, starting 24 h after seeding the cell in
culture. At least 3 samples were analysed and 20,000 events were
scored for each sample. The vertical axis represents the relative
number of events and the horizontal axis represents the
fluorescence intensity.
Figure 5 Flow cytometric analysis of cell cycle distribution of
human melanoma cells treated with 2. Human melanoma cell
lines HTB 66 (a) and 68 (b) were treated with 2 (1.3 mg/mL), for
24 h, starting 18 h after seeding the cell in culture. At least 3
samples were analysed and 20,000 events were scored for each
sample. The vertical axis represents the relative number of events
and the horizontal axis represents the fluorescence intensity.
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2 and 5-induced apoptosis is mediated through the im-
pairment of the ubiquitin-proteasome system.
When proteasome inhibitors prevent the proteasome
from activating NFκB, factors of angiogenesis, survival,
and growth are down regulated while apoptosis is up
regulated in multiple cell lines [43,44]. This effect is also
noticed in chemotherapy-resistant cells, additionally due
to disruption of proteasomal regulation of caspases and
Bcl2. Further, proteasome inhibition enhances the levels
of p21 and p27 [45]. Such enhancement inhibits CDKs
and consequently arrests cell cycle and halting the growth
of cancer cells. The inhibition of the proteolytic function
of the 26S proteasome has also been shown to impair
the development of new blood vessels from endothelial
cells or angiogenesis that is a vital factor for tumour
growth and metastasis [46]. Disruption of angiogenesis
by proteasome inhibition also occurs by decreasing mic-
rovessel density and the expression of vascular endothelial
growth factor (VEGF) [46]. Thus, the proteasomal inhib-
ition impairs angiogenesis as well as disturbs cellularhomeostasis, hence leading to an antitumor activity. Over-
all, the inhibition of the proteolytic function of the 26S
proteasome induces apoptosis and cell cycle arrest, and
represses angiogenesis as well as metastasis. In fact, apop-
tosis and other antitumor effects have been observed in
various cancer cell lines and xenograft models including
lymphoma, leukaemia, melanoma, pancreatic, prostate,
head and neck, breast, and lung cancers [47,48]. Further,
cancer cells are more sensitive to the cytotoxic effects of
the proteasome inhibition as compared to the normal
cells [49]. Also, cessation of all proteasomal function is
not required to achieve antitumor effects [50]. Together,
these studies have implicated the proteasome inhibition
as an attractive way of treating cancer cells. Several prote-
asome inhibitors have shown significantly improved anti-
tumor activities when combined with other drugs such as
HDAC inhibitors, Akt inhibitors, DNA damaging agent,
Hsp90 inhibitor, and lenalidomide. In summary, prote-
asome inhibitor alone or in combination with other ther-
apies have shown very promising results to treat cancer
patients in the clinic more effectively.
Table 1 Virtual binding scores of syringic acid analogues
and bortezomib
Compound Total score Crash Polar
Bortezomib 8.50 −2.13 2.26
4 6.59 −1.76 1.93
3 6.58 −1.43 3.11
6 6.32 −1.31 2.07
5 6.06 −1.18 3.13
2 5.43 −0.86 3.05
Syringic acid 3.83 −1.52 1.45
Using SYBYL-X Surflex-Dock and the eukaryotic yeast 20S proteasome crystal
structure (PDB code: 2 F16). Total score was expressed in –log (Kd) units to
represent binding affinities. Crash is the degree of inappropriate penetration
by the ligand into the protein and of interpenetration between ligand atoms
that are separated by rotatable bonds. Polar score is the contribution of the
polar non-hydrogen bonding interactions to the total score. The polar score
may be useful for excluding docking results that make no hydrogen bonds.
Figure 7 Assessment of apoptosis in human malignant
melanoma cells by annexin V-FITC and propidium iodide
staining. Untreated and derivative 2-treated (1.3 mg/mL, for 24 h)
human malignant melanoma cell lines HTB66 (a) and HTB68 (b)
were stained with annexin V-FITC and propidium iodide, then
analysed by flow cytometry. B4: percentage of early apoptotic cells,
B2: percentage of late apoptotic cells, B1: percentage of necrotic
cells and B3: living cells.
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syringic acid derivatives towards human malignant mel-
anoma cells may be associated with several mechanisms
which may be speculated to include disruption of cell
adhesion- and cytokine-dependent survival pathways, e.g.,
NFκB signalling pathway, inhibition of angiogenesis, ac-
tivation of a misfolded protein stress response (or ER
stress), up regulation of proapoptotic or down regula-
tion of antiapoptotic genes. DNA microarray analysis of
the expression of genes controlling these regulatory
mechanisms in melanoma cells-treated with syringic
acid derivatives will clarify the selectivity of the anti-
tumor activity of these derivatives against human ma-
lignant melanoma cells.
Molecular modelling studies
Bortezomib is the best described proteasome inhibitor
and the first to be clinically tested in humans, especially
against multiple myeloma and non-Hodgkin’s lymphoma.
Therefore, bortezomib was selected as a reference stand-
ard in this study. Bortezomib acts by binding β5i and β1i
proteasome subunits [7].
In its bound conformation, bortezomib adopts an anti-
parallel β-sheet conformation filling the gap between
strands S2 and S4. These β-sheets are stabilized by direct
hydrogen bonds between the conserved residues (Gly47N,Thr21N, Thr21O, and Ala49O) of the β-type subunits and
main chain atoms of the drug [21]. Both Thr21O and
Ala49N, conserved in all proteolytically active centres, are
essential for β-sheet formation. Their respective carbonyl
oxygen and nitrogen atoms tightly interact with bortezo-
mib’s pyrazine-2-carboxyl-phenylalanyl peptide backbone.
The binding mode and conformation was found to be uni-
form in all proteolytically active sites [21].
Docking of syringic acid derivatives showed that the
binding modes of energy-minimized derivatives are similar
to bortezomib bound conformation to crystal structure of
the eukaryotic yeast 20S proteasome which was obtained
from the Protein Database (PDB code: 2 F16).
2 demonstrated a good binding score presented in total
score as compared to bortezomib (Table 1). The carboxyl
moiety of the ester link of 2 formed three hydrogen bonds
with H/Thr1, H/Gly47 and H/Thr21. Furthermore, one
hydrogen bond was formed between the methoxyl group
and H/Thr52 as shown in Figure 8.
On the other hand, derivatives 3 and 4 showed the best
binding score, presented in total score, when compared to
other derivatives (Table 1). These results were in contrary
to what one would expect for in vitro activities, where 3
and 4 were shown to be the least active derivatives. One
reason for these unexpected low biological activities might
be their poor water-solubility when compared to the other
ones. In derivatives 3 and 4, the phenolic and carboxylic
hydroxyl groups were etherified and esterified, respect-
ively. This dramatically reduced their polarity, expected
water-solubility, and hence, limited their available critical
concentrations needed for bioactivities.
The carboxyl moiety of the ester linkage of 3 formed
two hydrogen bonds with H/Gly47 and H/Thr1. Another
hydrogen bond was present between one of the methoxyl
groups of syringic acid and H/Thr52, as shown in Figure 9.
On the other hand, the carboxyl moiety of the ester link-
age of 4 formed a hydrogen bond with H/Ala49. Another
Figure 8 Overlay docking alignment of derivative 2. Derivative 2 docked in the active site of 20S yeast proteasome (PDB code: 2 F16).
Selected structure is of 3D resolution 2.8 Å.
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groups of syringic acid and H/Thr1, while a third hydro-
gen bond was formed between the ether linkage and H/
Thr21. Additional hydrogen bond was also seen between
the m-methoxyl group of the newly added benzyl ether
moiety and H/Ser129 (Figure 10).
Moreover, 5 showed a slightly higher binding score than
2 (Table 1), however, it demonstrated a similar bindingFigure 9 Overlay docking alignment of derivative 3. Derivative 3
docked in the active site of 20S yeast proteasome (PDB code: 2 F16).
Selected structure is of 3D resolution 2.8 Å.conformation to 2 (Figure 11). Finally, 6 showed a com-
parable binding score and a similar docking conformation
to 3 (Figure 12).
Conclusions
Out of eighteen syringic acid derivatives virtually proposed,
only five derivatives; benzyl 4-hydroxy-3,5-dimethoxyben-
zoate (2), benzyl 4-(benzyloxy)-3,5-dimethoxybenzoate (3),
3′-methoxybenzyl 3,5-dimethoxy-4-(3′-methoxybenzyloxy)
benzoate (4), 3′-methoxybenzyl 4-hydroxy-3,5-dimetho-
xybenzoate (5) and 3′,5′-dimethoxybenzyl 4-hydroxy-3,5-Figure 10 Overlay docking alignment of derivative 4. Derivative
4 docked in the active site of 20S yeast proteasome (PDB code:
2 F16). Selected structure is of 3D resolution 2.8 Å.
Figure 11 Overlay docking alignment of derivative 5. Derivative
5 docked in the active site of 20S yeast proteasome (PDB code:
2 F16). Selected structure is of 3D resolution 2.8 Å.
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therefore, were chemically synthesized.
Syringic acid derivatives 2, 5 and 6 were shown to
inhibit human malignant cell growth, and proteasome
activity, and apoptosis inducers. Proteasome inhibitors
are considered promising anticancer agents. Therefore,
syringic acid derivatives 2, 5 and 6, with their safe profile
on normal human fibroblasts, have enormous potential
for future use for the prevention and control of human
malignant melanoma. The intimate coupling of multi-
component computer modelling with natural products-
based prospecting, in bidirectional fashion and the use
of in silico and in vitro tools for efficacy and selectivity
optimization, provide guidance and perfect examples of
rational drug discovery and design approaches.Figure 12 Overlay docking alignment of derivative 6. Derivative
6 docked in the active site of 20S yeast proteasome (PDB code:
2 F16). Selected structure is of 3D resolution 2.8 Å.Methods
Chemistry
The IR spectra were recorded as neat solids using an
FT/IR-4100 JASCO spectrophotometer. The 1H and 13C
NMR were obtained on a Bruker Avance II-600 spec-
trometer operating at 600 and 125 MHz, respectively.
Both 1H and 13C NMR spectra were recorded in CDCl3,
and the chemical shift values were expressed in δ (ppm)
relative to the internal standard TMS. For the 13C NMR
spectra, the number of attached protons was determined
by DEPT 135°. 2D NMR data were obtained using the
standard pulse sequence of the Bruker Avance II-600 for
COSY, HSQC, and HMBC. Mass Spectroscopy was car-
ried out using a Bruker Bioapex FTMS with Electrospray
Ionization Spectrometer. Thin layer chromatography
was performed on pre-coated (0.25 mm) silica gel GF254
plates (E. Merck, Germany) and compounds were visual-
ized via exposure to 254 nm UV lamp and spray with
p-anisaldehyde/ H2SO4 followed by heating.Benzyl 4-hydroxy-3,5-dimethoxybenzoate (2) and benzyl
4-(benzyloxy)-3,5 dimethoxybenzoate (3)
A solution of syringic acid (320 mg, 1.6 mmol) and
benzylbromide (1000 mg, 5.8 mmol) in N,N-dimethyl
formamide (20 mL) was heated under reflux. Sodium
hydride (38.4 mg, 1.6 mmol) was added portion-wise to
the reaction mixture. The mixture was kept under reflux
for 2 h. Reaction progress was monitored (thin layer
chromatography, solvent system: 100% chloroform) and
was shown go almost to completion. A saturated solution
of sodium carbonate (40 mL) was added to the reaction
mixture and, then, was extracted with chloroform
(40 mL × 3). The combined chloroform layer was dried
over anhydrous MgSO4, and evaporated in vacuo to
afford a yellowish syrupy residue (1.06 g). This residue
was chromatographed over flash silica gel column
(106 g) using chloroform as the eluting solvent. This
process afforded pure derivatives 2 (12 mg) and 3
(8 mg) as colourless oils. Spectral analysis confirmed
the identity of 2 as benzyl 4-hydroxy-3,5-dimethoxy-
benzoate and that of 3 as benzyl 4-(benzyloxy)-3,5-
dimethoxybenzoate. This reaction and chromatographic
processes were scaled up and repeated several times to
afford quantities enough to evaluate their biological
activities (189 mg of 2, and 124 mg of 3).
Derivative 2: yield, 2.6%; IR (neat, cm-1) ν max 3345
(O-H), 1725 (C = O); 1H NMR (CDCl3, 600 MHz) see
Table 2, supplemental data; 13C NMR (CDCl3, 125 MHz)
see Table 2, supplemental data; High resolution ESIMS
m/z 288.0942 [M]+ (calcd for C16H16O5 288.0998).
Derivative 3: yield, 1.3%; IR (neat, cm-1) ν max 1727 (C =
O); 1H NMR (CDCl3, 600 MHz) see Table 3, supplemental
data; 13C NMR (CDCl3, 125 MHz) see Table 3, supple-
Table 2 1H and 13C NMR assignments for syringic acid and its derivatives 2, 5 and 6a
Position Syringic acid 2 5 6
δC
b δH (m, J Hz) δC
b δH (m, J Hz) δC
c δH (m, J Hz) δC
b δH (m, J Hz)
1 128.6, C - 121.1, C - 121.1, C - 121.0, C -
2 107.0, CH 7.31 (s) 106.8, CH 7.36 (s) 106.9, CH 7.35 (s) 106.8, CH 7.38 (s)
3 148.0, C - 146.7,C - 146.7, C - 146.6, C -
4 142.6, C - 139.4, C - 139.4, C - 139.4, C -
5 148.0, C - 146.7, C - 146.7, C - 146.6, C -
6 107.0, CH 7.31 (s) 106.8, CH 7.36 (s) 106.9, CH 7.35 (s) 106.8, CH 7.38 (s)
1' - - 136.3, C - 137.9, C - 136.5, C -
2' - - 128.2, CH 7.45 (dd, 7.8, 1.2) 113.8d, CH 6.98 (d, 2.2) 105.9, CH 6.59 (d, 2.4)
3' - - 128.6, CH 7.39 (dd, 7.8, 7.2) 160.0, C - 160.9, C -
4' - - 128.2, CH 7.34 (dd, 7.2, 1.2) 113.7d, CH 6.88 (dd, 8.1, 2.2) 100.0, CH 6.45 (dd, 2.4, 2.4)
5' - - 128.6, CH 7.39 (dd, 7.8, 7.2) 129.8, CH 7.30 (dd, 10.0, 8.8) 160.9, C -
6' - - 128.2, CH 7.45 (dd, 8.8, 1.2) 120.4, CH 7.02 (d, 7.7) 105.9, CH 6.59 (d, 2.4)
7'-CH2 - - 66.7, CH2 5.36 (s) 66.8, CH2 5.32 (s) 66.5, CH2 5.30 (s)
3,5-OCH3 56.1, CH3 3.86 (s) 56.5, CH3 3.93 (s) 56.6, CH3 3.93 (s) 56.5, CH3 3.95 (s)
3'-OCH3 - - - - 55.3, CH3 3.82 (s) 55.4, CH3 3.82 (s)
5'-OCH3 - - - - - - 55.4, CH3 3.82 (s)
OH - 4.93 (s) - 5.92 (s) - 5.91 (br s) - 5.95 (s)
aSpectra recorded in CDCl3.
bMultiplicities were determined by DEPT 135. cMultiplicities were determined by APT. dAssignments may be interchanged.
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(calcd for C23H22O5 378.1467).3′-Methoxybenzyl 3,5-dimethoxy-4-(3′-methoxy benzyloxy)
benzoate (4) and 3′-methoxybenzyl 4-hydroxy-3,5-
dimethoxybenzoate (5)
Likewise, these derivatives were synthesized as men-
tioned above; however, 3-methoxybenzylbromide (920 mg,
4.6 mmol) was used, instead. Removal of un-reacted
syringic acid was achieved via adding saturated solution of
sodium carbonate and extraction with chloroform. Evap-
oration of chloroform layer yielded 1.03 g of a yellowish
syrupy residue. This residue gave, after purification, pure
derivatives 4 (10.6 mg) and 5 (15 mg) as pale yellow oils.
Derivatives 4 and 5 identities were deduced from their
spectral data. The reaction and purification processes were
repeated to yield 93 mg of 4 and 131 mg of 5.
Derivative 4: yield, 1.5%; IR (neat, cm-1) ν max 1727 (C =
O); 1H NMR (CDCl3, 600 MHz) see Table 3, supplemental
data; 13C NMR (CDCl3, 125 MHz) see Table 3, supple-
mental data; High resolution ESIMS m/z 438.1648 [M]+
(calcd for C25H26O7 438.1679).
Derivative 5: yield, 3%; IR (neat, cm-1) ν max 3340 (O-H),
1727 (C =O); 1H NMR (CDCl3, 600 MHz) see Table 2,
supplemental data; 13C NMR (CDCl3, 125 MHz) see
Table 2, supplemental data; High resolution ESIMS m/z
318.1110 [M]+ (calcd for C17H18O6 318.1103).3′,5′-dimethoxybenzyl 4-hydroxy-3,5-dimethoxy benzoate (6)
Following the above procedure, 3,5-dimethoxybenzyl-
bromide ( 320 mg, 1.7 mmol) was used. This reaction
was sluggish and never went to completion. Reaction
workup, afforded 0.166 g of a yellowish syrupy residue
which upon purification gave 5.4 mg of 6. Derivative 6
identity was confirmed from spectral analysis to be
3′,5′-dimethoxybenzyl 4-hydroxy-3,5-dimethoxybenzoate.
Reaction scale up afforded 52 mg of pure 6.
Derivative 6: yield, 1%; IR (neat, cm-1) ν max 3340 (O-H),
1721 (C =O); 1H NMR (CDCl3, 600 MHz) see Table 2,
supplemental data; 13C NMR (CDCl3, 125 MHz) see
Table 2, supplemental data; High resolution ESIMS m/z
348.1200 [M]+ (calcd for C18H20O7 348.1209).Biological activity
Cell Culture
All cell lines were obtained from ATCC (American Type
Culture, VA, USA). Human colorectal cancer cell lines
(CCL233 and CCL235) and Human breast cancer cell
lines (HTB131 and HTB132) were cultivated in Leibovitz’s
L15 medium, 90%, fetal bovine serum, 10%. L15-medium
formulation is devised for use in a free gas exchange with
atmospheric air. Human melanoma cell lines (HTB-66
and HTB-68) were cultivated in minimum essential med-
ium Eagle with 2 mM L-glutamine and Earle’s BSS ad-
justed to contain 1.5 g/L sodium bicarbonate, 0.1 mM
Table 3 1H and 13C NMR assignments for syrinigc acid
derivatives 3 and 4a
Position 3 4
δC
b δH (m, J Hz) δC
b δH (m, J Hz)
1 125.3, C - 125.2, C -
2 106.9, CH 7.31 (s) 107.0, CH 7.31 (s)
3 153.3, C - 153.2, C -
4 141.1, C - 141.2, C -
5 153.3, C - 153.2, C -
6 106.9, CH 7.31 (s) 107.0, CH 7.31 (s)
1' 136.1, C - 137.6, C -
2' 128.2, CH 7.44 (d, 7.8) 113.8, CH 7.44 (d, 7.8)
3' 128.5, CH 7.39 (dd, 7.8, 7.2) 159.8, C 7.39 (dd, 7.8, 7.2)
4' 128.0, CH 7.28 (dd, 7.2, 7.2) 113.6, CH 7.28 (dd, 7.2, 7.2)
5' 128.5, CH 7.39 (dd, 7.8, 7.2) 129.7, CH 7.39 (dd, 7.8, 7.2)
6' 128.2, CH 7.44 (d, 7.8) 120.4, CH 7.44 (d, 7.8)
1' 137.4, C - 138.9, C -
2' 128.2, CH 7.46 (d, 7.2) 113.5, CH 7.46 (d, 7.2)
3' 128.6, CH 7.34 (dd, 7.8, 7.2) 159.6, C 7.34 (dd, 7.8, 7.2)
4' 128.3, CH 7.32 (m) 113.9, CH 7.32 (m)
5' 128.6, CH 7.34 (dd, 7.8, 7.2) 129.2, CH 7.34 (dd, 7.8, 7.2)
6' 128.2, CH 7.46 (d, 7.2) 120.5, CH 7.46 (d, 7.2)
7'-CH2 66.8, CH2 5.36 (s) 66.7, CH2 5.36 (s)
7'-CH2 74.9, CH2 5.08 (s) 74.9, CH2 5.08 (s)
3,5-OCH3 56.3, CH3 3.86 (s) 56.3, CH3 3.86 (s)
3'-OCH3 - - 55.2
c, CH3
5'-OCH3 - - - -
3'- OCH3 - - 55.3
c, CH3 -
-COO- 166.2, C - 166.2, C -
OH - - - -
aSpectra recorded in CDCl3.
bMultiplicities were determined by DEPT 135.
cAssignments may be interchanged.
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Earl’s BSS, 90%, foetal bovine serum, 10%.
Normal human fibroblast cells (CCL1554) were culti-
vated in Eagle modified essential medium (90%) and foetal
bovine serum, 10%.
Dose-dependent anti-mitogenic effect of syringic
acid derivatives
The antimitogenic effects of syringic acid derivatives 2–
6 toward panel of different human cancer cell lines com-
prised of colorectal (CCL233, CCL235), breast (HTB26,
HTB132), breast (HTB26, HTB132), and melanoma
(HTB66 and HTB68) cancer cell lines as well as normal
human fibroblast CRL1554 cells were tested as previously
described [31]. Human cancer cell lines and normal hu-
man fibroblast cells were plated in 96-well microtiter
plates at a cell density of 27x103cells/well. Cells wereincubated in culture medium containing increasing con-
centrations of the tested derivatives (0.1, 0.4, 0.8, 1.2, 1.6
and 2.0 mg/mL) at 37°C in CO2 or non CO2 incubator
depending on the cell lines for 144 h. On the completion
of the treatment period, the media were discarded and
100 μl/well of MTT (5 mg/mL in culture medium filtered
sterilized) was then added and the plate was incubated
for 4 h at 37°C. The MTT solution was then aspirated
and the formazan crystals were dissolved in 200 μl/well
of 1:1 (v/v) solution of DMSO: ethanol for 20 min at
ambient temperature. Change in absorbance was deter-
mined at A540 and 650 nm. Derivatives 2 (50–400 μg/
mL), 5 (100–800 μg/mL) and 6 (260–400 μg/mL) were
retested for their antimitogenic activities against human
malignant melanoma cancer cell lines HTB66 and HTB68
and normal human fibroblast CRL1554 after 24 h of treat-
ment as mentioned above.
Cell extract preparation
A whole-cell extract was prepared as previously described
[7]. Briefly, human melanoma Cancer cells HTB68 were
grown to 60-70% confluency, harvested, washed twice
with PBS and homogenized in a lysis buffer (50 mM Tris
(pH 8.0), 5 mM ethylenediaminetetraacetic acids, 150 mM
NaCl, 0.5% NP40). After 30 minutes of rocking at 4°C, the
mixtures were centrifuged at 14,000× g for 30 minutes
and the supernatants were collected as whole-cell extracts.
Inhibition of the proteasome activities in human melanoma
whole cell extracts by derivatives 2, 5 and 6
Various proteasomal activities were determined in human
melanoma whole cell extract as previously described [31].
Briefly, human melanoma cancer cell extract (6 μg) was
incubated for 90 min at 37°C with 20 μM fluorogenic
peptide substrates: Suc-Leu-Leu-Val-Tyr-AMC (for protea-
somal chymotrypsin-like activity), benzyloxycarbonyl(Z)-
Leu-Leu-Glu-AMC (for proteasomal PGPH activity) and
Z-Gly-Arg-AMC (for proteasomal trypsin-like activity) in
100 μl of the assay buffer in the presence or absence of
Derivatives 2 (1.5 mg/mL), 5 (2.6 mg/mL) and 6 (1.75 mg/
mL). After incubation, the reaction mixture was diluted to
200 μL with the assay buffer followed by a measurement
of the hydrolysed 7-amido-4-methyl-coumarin (AMC)
groups using aVersaFluor™ Fluorometer with an excitation
filter of 380 nm and emission filter of 460 nm.
Flow cytometric analysis of cell cycle
The distribution of cells in cell cycle phases (Go/G1, S,
G2/M) was determined using flow cytometry by the
measurement of the DNA content of nuclei labelled with
propidium iodide as previously described [51]. Briefly,
human melanoma cell lines HTB66 and HTB68 were
plated (2.5×105 cells/mL) into 24-well plates and incu-
bated at 37°C in CO2 incubator. Cells were treated with
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starting 18 h after seeding the cells in culture. Untreated
and derivative 5-treated human melanoma cells were
collected by trypsinization and then washed with cold
phosphate buffered saline (PBS) and then counted.
Cells were processed using DNA-prep kit (Beckman
and Coulter, FL, USA) and a DNA-Prep EPICS work-
station (Beckman and Coulter). During this process,
cells were treated with a cell-membrane permeabilizing
agent and then with propidium iodide (PI) and RNAase.
The sample was then incubated at room temperature
for 15 minutes before analysing by aligned flow cytom-
etry (FC500, Beckman and Coulter). The percentage of
cells in different cell cycle phases was calculated using
the Phoenix statistical software package and Advanced
DNA cell cycle software (Phoenix Flow System, San
Diego, CA, USA).
Assessment of apoptosis by Annexin V-FITC and PI staining
The potential of derivatives 2 and 5 to induce apoptosis
in human melanoma cells was determined by Annexin
V-FITC and PI staining (Annexin V-FITC, BD Pharmingen,
San Diego, CA, USA) and according to the manufacturer’s
instruction. Briefly, human melanoma cell lines HTB66 and
HTB68 were plated (2.5 × 105 cells/mL) into 24-well plate
and incubated at 37°C in CO2 incubator. Cells were treated
with derivatives 2 (1.3 mg/mL) and 5 (1.9 mg/mL) for 24 h.
Cells from control and treatment groups were re-sus-
pended in 100 μl staining solution containing V fluorescein
and propidium iodide in HEPES buffer. Following incuba-
tion at room temperature for 15 min, cells were analysed
by flow cytometry. Annexin V binds to those cells that
express phosphatidylserine on the outer layer of the cell
membrane, and propidium iodide stains the cellular
DNA of those cells with a compromised cell membrane.
This allows for the discrimination of live cells (unstained
with either fluorochrome) from apoptotic cells (stained
only with V) and necrotic cells (stained with both V and
propidium iodide).
Molecular modelling studies
Three-dimensional structure building and all modelling
were performed using the SYBYL Program Package,
version X [52], installed on a DELL desktop workstation
equipped with a dual 2.0 GHz Intel® Xeon® processor
running the Red Hat Enterprise Linux (version 5) operat-
ing system. Conformations of bortezomib and syringic
acid derivatives 2–6 were generated using Confort™ con-
formational analysis. Energy minimizations were performed
using the Tripos force field with a distance-dependent
dielectric and the Powell conjugate gradient algorithm
with a convergence criterion of 0.01 kcal/(mol A). Partial
atomic charges were calculated using the semiempirical
program MOPAC 6.0 and applying the AM1.Surflex-Dock Program version 2.0 interfaced with SYB
YL-X was used to dock TMC-95A, bortezomib and sy-
ringic acid derivatives 2–6 in the active site of 20S yeast
proteasome (PDB code: 2 F16 and 1JD2). Surflex-Dock
employs an idealized active site ligand (protomol) as a
target to generate putative poses of molecules or molecu-
lar fragments [53]. These putative poses were scored using
the Hammerhead scoring function [53,54]. The 3D struc-
tures (PDB: 2 F16 and 1JD2) were taken from the Re-
search Collaboratory for Structural Bioinformatics Protein
Data Bank (http://www.rcsb.org/pdb).
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